BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myalept (metreleptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Myalept (metreleptin)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06305182-129@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Myalept (metreleptin): Phase 2 readout est. (NCT06305182)
DESCRIPTION:Myalept (metreleptin)\, phase 2.\nStudy: Metreleptin in Anorexi
 a Nervosa\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/metreleptin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06305182
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02262806-129@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Myalept (metreleptin): Phase 2 readout est. (NCT02262806)
DESCRIPTION:Myalept (metreleptin)\, phase 2.\nStudy: Compassionate Use of M
 etreleptin in Previously Treated People With Partial Lipodystrophy\nEstima
 ted primary completion: 31 July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02262806
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02262832-129@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Myalept (metreleptin): Phase 3 readout est. (NCT02262832)
DESCRIPTION:Myalept (metreleptin)\, phase 3.\nStudy: Compassionate Use of M
 etreleptin in Previously Treated People With Generalized Lipodystrophy\nEs
 timated primary completion: 31 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT02262832
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06484868-129@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Myalept (metreleptin): Phase 4 readout est. (NCT06484868)
DESCRIPTION:Myalept (metreleptin)\, phase 4.\nStudy: Open-label Study to Ev
 aluate Metreleptin in Patients With Partial Lipodystrophy\nEstimated prima
 ry completion: February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/metreleptin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06484868
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679270-129@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Myalept (metreleptin): Phase 3 readout est. (NCT06679270)
DESCRIPTION:Myalept (metreleptin)\, phase 3.\nStudy: Open-label Extension S
 tudy to Evaluate Metreleptin in Patients With Partial Lipodystrophy\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06679270
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
